Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Exploiting emerging ideas in G protein-coupled receptor biology and pharmacology to treat asthma

Award Number: P01HL180318
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/20/2025
PERIOD OF PERFORMANCE END DATE: 07/31/2030

Group Awards By:

View Award Description

Exploiting emerging ideas in G protein-coupled receptor biology and pharmacology to treat asthma - Overall Program Abstract For this NHLBI PPG we have assembled a highly collaborative team of experts in G protein-coupled receptor (GPCR) biology, airway smooth muscle (ASM) biology, and asthma biology to pursue the theme of “exploiting emerging ideas in G protein-coupled receptor biology and pharmacology to treat asthma.” The Program expects to achieve the following goals: 1) Identify novel targets and targeting molecules involving GPCR regulation of ASM contraction and proliferation; 2) Delineate the mechanisms by which these novel targets/targeting molecules regulate these ASM functions; and 3) Establish the therapeutic utility of novel targeting molecules in in vivo models of asthma. These goals will be accomplished across 4 scientific projects, two scientific cores, and an administrative core, to test the central hypothesis that novel modes of GPCR regulation can be targeted to effect superior management of ASM function and asthma. Each project takes advantage of a robust experimental strategy that incorporates multiple cell, tissue, and in vivo models of ASM function, complemented by cutting-edge biochemical analyses to detail mechanisms of action. Project 1 will test the ability of, and mechanisms effected by, recently-developed biased β2AR ligands to manage ASM contractility and the asthma phenotype, while (with Core A) leveraging recent insight in β2AR structure-activity relationship to develop new ligands superior to in-hand leads. Project 2 pivots away from the receptor locus as a means to regulate GPCR control of ASM, to explore the role of the cAMP transport inhibitor ABBC1, positing that ABBC1- dependent pathways inhibit β-agonist effects on HASM E-C coupling, and are upregulated in asthma patients. Project 3 similarly explores regulation of downstream Gq-coupled receptor signaling by diacylglycerol kinase (DGK), whose targeting effectively inhibits pro-contractile and pro-mitogenic GPCR signaling in ASM to control the asthma phenotype. Project 4 breaks new ground in the exploration of Class C GPCRs, clarifying the roles of GPRC5A and GPRC5B in ASM and asthma biology, and in collaboration with Core A, developing new ligands to skew the signaling competition between these 2 receptors towards therapeutically beneficial GPRC5A signaling and away from pathogenic GPRC5B signaling. The four projects will be supported by Core A, which will employ high-throughput screening of diverse libraries of arrayed and expressed small molecules, and further employ structural biology, computational modeling and virtual screening to leverage screening results, predict and test novel drug-like molecules. Core B will provide all de-identified human cell and tissue models to study novel mechanisms regulating EC coupling in HASM. Core C will provide administrative support for the program. Each project also collaborates with other projects to test combination strategies that target receptors (β2AR, GPR5A, GPR5B) in conjunction with downstream regulators (ABCC1, DGK). The strengths of this Program are the common focus on a single theme and the productive working relationship among investigators with the ability to apply cutting-edge GPCR biology to key questions in asthma biology and pharmacology.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $2,325,263 )
2026	2026	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST STE 1	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Lung Diseases Research	000	2	9/11/2026	NON-COMPETING CONTINUATION	$2,325,263
														Subtotal = $2,325,263

Issue Date FY: 2025 ( Subtotal = $2,456,717 )
2025	2025	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST STE 1	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Lung Diseases Research	000	1	9/16/2025	NEW	$2,456,717
														Subtotal = $2,456,717

Grand Total All Awards = $4,781,980

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Exploiting emerging ideas in G protein-coupled receptor biology and pharmacology to treat asthma

Award Number: P01HL180318

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/20/2025

PERIOD OF PERFORMANCE END DATE: 07/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer